Related references
Note: Only part of the references are listed.The novel atypical antipsychotic cariprazine demonstrates dopamine D2 receptor-dependent partial agonist actions on rat mesencephalic dopamine neuronal activity
Sarah Delcourte et al.
CNS NEUROSCIENCE & THERAPEUTICS (2018)
Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial
Gyorgy Nemeth et al.
LANCET (2017)
Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology
Jo C. Neill et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2016)
The dopamine D3-preferring D2/D3 dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia
David J. G. Watson et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2016)
Current drug treatments targeting dopamine D3 receptor
Gian Marco Leggio et al.
PHARMACOLOGY & THERAPEUTICS (2016)
Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO
Ragy R. Girgis et al.
PSYCHOPHARMACOLOGY (2016)
Cariprazine in Negative Symptoms of Schizophrenia: Post-hoc Analyses of a Fixed-dose Phase Iii, Randomized, Double-blind, Placebo-and Active-controlled Trial
M. Debelle et al.
EUROPEAN PSYCHIATRY (2015)
Cariprazine in Acute Exacerbation of Schizophrenia: A Fixed-Dose, Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Trial
Suresh Durgam et al.
JOURNAL OF CLINICAL PSYCHIATRY (2015)
Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia Results From an International, Phase III Clinical Trial
John M. Kane et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2015)
An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial
Suresh Durgam et al.
SCHIZOPHRENIA RESEARCH (2014)
Cariprazine, a dopamine D3-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse
Ross Zimnisky et al.
PSYCHOPHARMACOLOGY (2013)
Selective Blockade of Dopamine D3 Receptors Enhances while D2 Receptor Antagonism Impairs Social Novelty Discrimination and Novel Object Recognition in Rats: A Key Role for the Prefrontal Cortex
David J. G. Watson et al.
NEUROPSYCHOPHARMACOLOGY (2012)
Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents
Istvan Gyertyan et al.
NEUROCHEMISTRY INTERNATIONAL (2011)
Effects of antipsychotics on D3 receptors: A clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO
Romina Mizrahi et al.
SCHIZOPHRENIA RESEARCH (2011)
Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist-Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile
Bela Kiss et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
The Effect of Antipsychotics on the High-Affinity State of D2 and D3 Receptors A Positron Emission Tomography Study With [11C]-(+)-PHNO
Ariel Graff-Guerrero et al.
ARCHIVES OF GENERAL PSYCHIATRY (2009)
Blockade of dopamine D-3 receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: Similar actions of D-1 receptor agonists, but not of D-2 antagonists
Florence Loiseau et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2009)
Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15
Istvan Gyertyan et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2008)
Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15
Bela Kiss et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2008)
Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists
Gregory T. Collins et al.
PSYCHOPHARMACOLOGY (2007)
Synthesis and SAR of highly potent and selective dopamine D3-receptor antagonists:: Variations on the 1H-pyrimidin-2-one theme
H Geneste et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
Dopamine agonist-induced yawning in rats: A dopamine D3 receptor-mediated behavior
GT Collins et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Selective antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex
LP Lacroix et al.
NEUROPSYCHOPHARMACOLOGY (2003)
Share Paper
